Tag Archives: patents

SACGHS Final Report on Gene Patents – Taking a Machete to the IP Thicket

Posted on February 5, 2010 by Warren Woessner

On September 17, 2009, the Secretary of HHS’s Advisory Committee on Genetics, Health and Society (SACGHS) issued a Final Draft Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. The 66 page report … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged gene patents, patents, SACGHS, Warren Woessner | Leave a comment

TRANSMISSION OF INFORMATION IN EUROPE – PATENTABLE SUBJECT MATTER?

Posted on November 17, 2009 by Warren Woessner

By Paul Cole, Lucas & Co., UK The UK counterpart of In re Ngai is Bayer’s (Meyer’s) Application [1984] R.P.C. 11. In that case a claim to a package containing a known drug together with instructions for a new use … Continue reading →

Posted in Non-U.S. Practice | Tagged Bayer's Application, business methods, EPO, intellectual property, patents, Paul Cole, UK, Warren Woessner | Leave a comment

OUTSIDE OPINIONS ARE STILL KEY TO AVOIDING WILLFUL INFRINGEMENT

Posted on November 5, 2009 by Warren Woessner

By A. J. Nelson The October 29th IPO summary reports on the Senate version of the bill (attached below) regarding willful infringement: SENATE BILL CODIFIES SEAGATE STANDARD FOR WILLFUL INFRINGEMENT AND IMPOSES ADDITIONAL LIMITATIONS ON FINDING WILLFULNESS — Section 4 … Continue reading →

Posted in Opinion Practice | Tagged FTO, IPO, Jim Nelson, Patent Law, patent opinions, patents, Seagate, Senate | Leave a comment

Guessing Right Is Not Sufficient — The Ghost Of Rasmusson Walks Among Us!

Posted on September 29, 2009 by Warren Woessner

Rasmussen v. SmithKline Beecham Corp., 413 F.3d 1318 (Fed. Cir. 2005) (link below) was a truly scary decision that many of us practitioners hoped would be ignored by future Fed. Cir. panels as an aberration brought on by over-extensive prosecution, … Continue reading →